RP5063 shows positive signs for the treatment of schizophrenia

A new drug has been shown to be potentially effective for the treatment of schizophrenia.

A Phase 2 clinical trial has shown the dopamine serotonin stabiliser RP5063 may be effective for the treatment of schizophrenia and schizoaffective disorder.
That is according to Reviva Pharmaceuticals, which explained the trial was carried out across 234 patients in the US, Asia and Europe.
Participants with schizophrenia or schizoaffective disorder were randomised and treated for a month with either RP5063 at doses of 15mg, 30mg or 50mg per day, or a placebo or control arm of aripiprazole at 15mg.
"The favourable tolerability data also lends support to trials in even more fragile populations such as geriatrics and pediatrics," said study investigator Mark Novitsky.
According to the results of the research, there were no clinically significant differences in systematic side effects between RP5063 and the placebo drug, including motor function.
There was also no apparent side effects in prolactin related sexual problems which the study observed are a common side effect of current antipsychotic treatments.